Tuesday, October 4, 2022


Biotechnology News Magazine

NovaXS Biotech Wows Judges and Audience at Silicon Valley Startup Competition

Berkeley SkyDeck Pad-13 pitch competition selects needle-free therapy device as 2022 winner

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

NovaXS Biotech Corp (NovaXS), developers of an in-home and needle-free drug delivery platform, won first-place and was voted as Audience Favorite at the Berkeley SkyDeck Pad-13 Pitch Competition. NovaXS’s Founder and CEO Alina Su and her team provided a demonstration of their Telosis device which aims to provide an easy and painless alternative to administer drugs at home without needles to make healthcare more accessible.

“NovaXS Biotech is honored to be selected as the champions and audience favorite of the Berkeley SkyDeck Pitch Competition, especially out of all the impressive startups in attendance,” said Alina Su, CEO and Founder of NovaXS. “When my sister was younger, she was diagnosed with a disease that required daily needle injections for treatment. I witnessed her pain and the inefficiencies in self-administered drug delivery first-hand which is why me and my team are so dedicated to developing this solution.”

At the competition, NovaXS and eleven other startups in the technology, communications, healthcare, and other industries, showcased their products to SkyDeck advisors, mentors, alumni and investors. NovaXS was selected for its strong business potential and ability to transform healthcare delivery. The product prototype is a device that administers a narrow stream of medication without a needle and analyzes injection data. NovaXS is focused on making the drug delivery process a better experience for patients with diabetes, growth hormone deficiencies, allergies and IVF therapies.

“NovaXS Biotech strives to lower the barrier for healthcare access. We’re currently working on the FDA clearance to use our device and platform on the human body. Working with our SkyDeck mentors Cathy Farmer, Darren Cooke, Caroline Winnett and Sibyl Chen to refine our value proposition and provide industry insights is so valuable as we work toward our goals,” added Su.

NovaXS is a member of the Berkeley SkyDeck program and also won first place in the Berkeley Fall 2021 Collider Cup held by Berkeley Sutardja Center for Entrepreneurship and Technology. NovaXS Biotech is also enrolled in the mHub MedTech Accelerator, USC Troylabs and Newchip Accelerator.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine